NAD+ Decline in Aging: Sirtuins, PARP Competition, CD38 Drain, and the Precursor Debate

Why NAD+ Is the Currency of Cellular Longevity

Nicotinamide adenine dinucleotide — NAD+ — is one of the most ancient molecules in biology. Every living cell on earth uses it. In human cells, it serves two distinct roles that are both essential and, at high age, increasingly in conflict with each other.

First, NAD+ is a redox cofactor. In its oxidized form (NAD+) it accepts electrons from metabolic reactions; in its reduced form (NADH) it donates them to the mitochondrial electron transport chain to generate ATP. This is textbook biochemistry taught in every undergraduate biology course.

Second — and this is what makes NAD+ central to aging biology — NAD+ is a substrate consumed by a class of signaling enzymes including sirtuins, PARPs, and CD38. When these enzymes act, they don't just use NAD+ as a cofactor they recycle. They cleave it apart, releasing nicotinamide and producing various ADP-ribose products. NAD+ is destroyed in the process and must be replenished.

The problem is that NAD+ synthesis slows as we age while NAD+-consuming enzymes either upregulate or become more active. The result is a progressive cellular energy and signaling crisis that correlates — causally in animal models and associatively in humans — with virtually every hallmark of aging.

The NAD+ Biosynthesis Pathways

The human body makes NAD+ through three distinct routes, and understanding each matters for choosing the right precursor strategy.

The de novo pathway synthesizes NAD+ from dietary tryptophan through a multi-step process called the kynurenine pathway. It is metabolically expensive and contributes only a minor fraction of total NAD+ in most tissues. Importantly, expression of the rate-limiting enzyme ACMSD increases with age and obesity, diverting tryptophan away from NAD+ and toward other metabolites. Inhibiting ACMSD has been proposed as a way to boost NAD+ without supplementing precursors directly.

The Preiss-Handler pathway converts nicotinic acid (niacin, NA) to NAD+ via a three-enzyme sequence. This is the pathway targeted by high-dose niacin therapy. It is efficient and well-characterized, but nicotinic acid at effective doses causes the notorious "niacin flush" — a prostaglandin-mediated vasodilation that most people find uncomfortable.

The salvage pathway is the dominant route for NAD+ synthesis in most human tissues and the one targeted by NMN and NR supplementation. The key enzyme here is NAMPT (nicotinamide phosphoribosyltransferase), which converts nicotinamide — the end product released when sirtuins and PARPs consume NAD+ — back into NMN, which is then converted to NAD+. NAMPT is the rate-limiting bottleneck of this pathway, and its expression declines significantly with age, partly explaining why recycling becomes less efficient over time.

How NAD+ Levels Decline with Age

Longitudinal and cross-sectional studies using mass spectrometry and enzymatic assays consistently show NAD+ declining with age in blood, muscle, liver, brain, and skin. The trajectory is roughly linear from early adulthood, with the steepest relative losses in metabolically active tissues.

Skeletal muscle data from the Guarente lab and others show 60-65% reductions in NAD+ content in aged versus young subjects. Circulating NAD+ in whole blood declines approximately 1-2% per year from the third decade onward. Cerebrospinal fluid NAD+ levels — difficult to measure and thus less studied — appear to follow similar trends, with potential consequences for neuronal function.

Three mechanisms drive this decline simultaneously: reduced synthesis capacity (lower NAMPT, slower de novo pathway), increased consumption by chronically activated PARPs and CD38, and mitochondrial dysfunction that creates a demand for more NADH recycling without a compensatory increase in NAD+ synthesis.

The Seven Sirtuins: Guardians of the Genome and Metabolism

When David Sinclair and Leonard Guarente identified sirtuins as potential longevity regulators in the late 1990s, NAD+ biology entered the mainstream of aging research. The original observation — that SIR2 in yeast extended lifespan in a NAD+-dependent manner — launched a field that two decades later remains one of the most active in longevity science.

Humans have seven sirtuin paralogs (SIRT1-7), each with distinct subcellular locations, substrates, and physiological functions. All share the requirement for NAD+ as a co-substrate — without it, they are catalytically inert.

SIRT1: The Master Regulator

SIRT1 is the most studied mammalian sirtuin and arguably the most important for longevity. It is a nuclear deacetylase that regulates hundreds of downstream targets including p53 (DNA damage response), FOXO transcription factors (stress resistance and autophagy), PGC-1α (mitochondrial biogenesis), NF-κB (inflammation), and HIF-1α (hypoxia response).

SIRT1 activity declines in aged tissues in parallel with NAD+ decline — a key observation because SIRT1 has a Km for NAD+ that sits right in the physiological range, meaning small changes in NAD+ availability cause proportional changes in SIRT1 activity. This is not a coincidence. It means SIRT1 is exquisitely calibrated to act as a cellular sensor of metabolic status: when NAD+ is high (fed, exercising, caloric restriction), SIRT1 is active and promotes cellular maintenance. When NAD+ falls (aging, sedentary, obesogenic diet), SIRT1 activity drops and maintenance programs slow.

Sinclair's information theory of aging frames this as the central mechanism: SIRT1 loss leads to epigenetic noise accumulation — histones are incorrectly acetylated, gene expression drifts from youthful patterns, and cells forget what cell type they are. Restoring SIRT1 activity via NAD+ repletion, in his model, is a form of epigenetic reprogramming.

SIRT3: The Mitochondrial Sentinel

SIRT3 resides exclusively in the mitochondrial matrix and deacetylates dozens of metabolic enzymes including those involved in the TCA cycle, fatty acid oxidation, and the electron transport chain. Critically, SIRT3 activates mitochondrial superoxide dismutase (SOD2), the primary antioxidant defense against mitochondrial reactive oxygen species.

SIRT3 knockout mice develop accelerated aging phenotypes including hearing loss, metabolic dysfunction, and elevated cancer risk — phenotypes that overlap strikingly with normal human aging. SIRT3 expression correlates with longevity in human centenarian studies, and polymorphisms in the SIRT3 gene have been associated with exceptional longevity in some populations.

For practical purposes, SIRT3 activation via NAD+ repletion represents one of the most direct paths to improving mitochondrial function in aging tissues.

SIRT2, SIRT5, SIRT6, and SIRT7

SIRT2 is primarily cytoplasmic and deacetylates tubulin and other cytoskeletal proteins. It has emerging roles in genome integrity during mitosis and may protect against neurodegenerative disease. SIRT5 is mitochondrial with unique desuccinylase and demalonylase activities, regulating ammonia detoxification. SIRT6 is nuclear and specializes in maintaining telomere stability, DNA double-strand break repair, and suppressing glycolysis via HIF-1α deacetylation. SIRT7 is nucleolar and regulates ribosomal RNA transcription and protein homeostasis.

The full functional map of SIRT6 is particularly exciting: SIRT6 overexpression extends lifespan in male mice by 15%, and SIRT6 appears to be the sirtuin most directly linked to suppressing the DNA damage response. It is highly sensitive to NAD+ availability and represents a compelling mechanism linking NAD+ decline to genomic instability — itself a hallmark of aging.

The NAD+/Sirtuin Feedback Loop

SIRT1 and SIRT3 do not passively respond to NAD+ levels — they actively regulate NAD+ synthesis. SIRT1 deacetylates and activates NAMPT gene expression; SIRT3 improves mitochondrial function and reduces oxidative stress, which would otherwise damage NAMPT. This creates a positive feedback loop in youth: high NAD+ supports sirtuin activity, which maintains NAMPT, which sustains NAD+. In aging, the loop inverts: declining NAD+ reduces sirtuin activity, NAMPT expression falls, NAD+ drops further.

PARP Competition: DNA Repair vs. Longevity Signaling

Poly(ADP-ribose) polymerases — PARPs — are a family of 17 enzymes in humans, of which PARP1 is by far the most abundant and metabolically significant. PARP1 is the cell's emergency responder for DNA damage. When a DNA strand breaks — caused by reactive oxygen species, ionizing radiation, replication errors, or any of dozens of other insults — PARP1 binds the break site within seconds and begins consuming NAD+ at extraordinary rates to synthesize poly-ADP-ribose (PAR) chains on itself and surrounding chromatin proteins.

This PAR signaling recruits the DNA repair machinery, stabilizes the break site, and coordinates the cellular response. In a young cell with abundant NAD+, this system functions beautifully. The problem in aging is twofold.

The PARP1 Drain in Aged Cells

First, aged cells accumulate more DNA damage — from a lifetime of oxidative stress, telomere shortening, replication errors, and environmental insults. More DNA breaks mean more PARP1 activation, more NAD+ consumption, and less NAD+ left for sirtuins and mitochondrial function. Second, unresolved DNA damage triggers sustained PARP1 activation that can deplete local and even systemic NAD+ pools to near-zero, causing cell death via a process called parthanatos (PARP-dependent cell death) — distinct from apoptosis and necrosis.

The competition between PARP1 and SIRT1 for NAD+ is direct and documented. Both enzymes have Km values for NAD+ in the low micromolar range that is physiologically relevant. Under conditions of acute DNA damage, PARP1 outcompetes SIRT1 for NAD+ by sheer catalytic throughput: PARP1 can consume NAD+ hundreds of times faster than sirtuins. This transiently suppresses sirtuin activity precisely when it may be most needed.

PARP Inhibitors as Longevity Tools?

The therapeutic use of PARP inhibitors (PARPi) in cancer treatment — approved for BRCA-mutated cancers — has renewed interest in PARP biology as it relates to aging. If PARP1 is a major NAD+ drain in aged tissues, could low-dose PARPi extend longevity by preserving NAD+ for sirtuins?

Animal data are intriguing: olaparib (a clinical PARPi) extends C. elegans lifespan. Nicotinamide, the endogenous PARP inhibitor released when NAD+ is cleaved, has been used at high doses in some human longevity protocols, though it also inhibits sirtuins at the same doses — a crucial pharmacological complication.

The practical takeaway: rather than pharmacologically inhibiting PARP (which could compromise DNA repair and increase cancer risk), the safer approach is to maintain sufficient NAD+ reserves that both PARP1 and sirtuins can function normally without entering a competition for a depleted substrate pool.

PARP14, PARP7, and the Inflammatory Connection

Beyond PARP1, mono-ADP-ribosyltransferases like PARP14 and PARP7 play roles in inflammatory signaling through the macrodomain-containing family. PARP14 is activated by IL-4 and promotes pro-survival signaling; PARP7 modulates innate immune response. In the context of aging and chronic inflammation ("inflammaging"), these enzymes contribute to sustained low-level NAD+ consumption independent of acute DNA damage — a slow background drain that compounds over decades.

CD38: The Age-Amplified NAD+ Destroyer

If sirtuins represent the prize for maintaining NAD+ and PARPs represent the emergency drain, CD38 is the chronic leak that may be responsible for the bulk of age-related NAD+ decline. CD38 (cluster of differentiation 38) is an ectoenzyme — it sits on the cell surface and within intracellular membranes — that functions primarily as an NAD+ glycohydrolase: it cleaves NAD+ into nicotinamide and ADP-ribose or cyclic ADP-ribose (cADPR), the latter being a potent second messenger for intracellular calcium release.

Why CD38 Rises with Age

CD38 expression is minimal in young, healthy tissues but increases dramatically with age, obesity, and particularly with chronic inflammation. Senescent cells — the "zombie cells" that accumulate with age and cannot divide or die normally — express very high levels of CD38. The senescence-associated secretory phenotype (SASP) includes inflammatory cytokines that upregulate CD38 in neighboring cells, spreading the NAD+ drain in a paracrine fashion.

Cabreiro and colleagues showed that CD38 knockout mice maintain elevated NAD+ levels into old age and display improved metabolic function. The landmark 2016 paper by Camacho-Pereira et al. in Cell Metabolism demonstrated that CD38, not PARP, accounts for the majority of NAD+ degradation in aged mouse livers — overturning the prior assumption that PARP was the primary consumer.

Furthermore, CD38 is dramatically induced by systemic inflammation: LPS, TNF-α, and IL-6 all upregulate CD38 within hours, creating a mechanism by which acute illness or chronic low-grade inflammation can acutely deplete NAD+. This may explain why older adults recovering from illness recover more slowly — their already-reduced NAD+ reserves are further depleted by the inflammatory CD38 response.

Targeting CD38: Apigenin, Quercetin, and Beyond

Several natural compounds have been identified as CD38 inhibitors. Apigenin — a flavonoid found in parsley, chamomile, and celery — inhibits CD38 in vitro at low micromolar concentrations and raises NAD+ in mouse tissues. Quercetin, luteolin, and kuromanin show similar activity. These compounds are unlikely to achieve pharmacologically relevant CD38 inhibition from dietary intake alone, but dedicated supplementation or pharmaceutical inhibitors represent an active area of research.

The advantage of targeting CD38 over other interventions is that it addresses a root cause of age-related NAD+ decline rather than simply adding more precursor substrate. A combination approach — inhibiting CD38 while also supplying NR or NMN — theoretically provides synergistic NAD+ elevation.

Precursor Pathways: NMN vs. NR vs. Niacin vs. Nicotinamide

Understanding the biochemistry of NAD+ precursors is essential for navigating the supplement market, which is crowded with competing claims and marketing that frequently outpaces the evidence. Each precursor has distinct pharmacokinetics, target tissues, and safety profiles.

Nicotinamide Riboside (NR)

NR is a pyridine-nucleoside form of vitamin B3 discovered as an NAD+ precursor by Charles Brenner in 2004. It enters cells via nucleoside transporters and is rapidly phosphorylated to NMN by NR kinases (NRK1 and NRK2), which are then converted to NAD+ by NMNAT enzymes in the cytoplasm and nucleus.

NR has the most published human clinical trial data of any NAD+ precursor. Multiple phase 1 and phase 2 trials demonstrate dose-dependent increases in whole blood NAD+ ranging from 40% to 200% above baseline with doses of 250mg-2000mg daily. NR is well-tolerated, does not cause flushing, and its metabolites (MeNAM, Me2PY) can be measured in urine as pharmacodynamic biomarkers.

The question is whether raising blood NAD+ with NR translates to meaningful tissue-level changes in SIRT1 activity, PARP function, or clinical outcomes. Encouraging signals include improved muscle mitochondrial function in older adults (Elhassan et al., 2019), reduced blood pressure in a subset of hypertensive patients, and improved cognitive function in some pilot studies — though none of these findings are definitive in isolation.

Nicotinamide Mononucleotide (NMN)

NMN is one step further along the NAD+ biosynthesis pathway than NR. For years, its cellular uptake mechanism was unclear — NMN is a nucleotide and does not have established nucleotide transporters in most mammalian cells. Research by Yoshino et al. identified a specific NMN transporter (Slc12a8) in the small intestine, providing a possible direct uptake mechanism for gut cells.

For most other tissues, the current consensus is that NMN is dephosphorylated to NR in the bloodstream or intestinal lumen before being transported into cells and re-phosphorylated to NMN — making NR and NMN functionally equivalent for most tissues. However, tissues expressing Slc12a8 (particularly intestinal cells) may preferentially use NMN.

Human trials of NMN — primarily from Japanese and US groups — show similar magnitude NAD+ increases to NR. A 2022 trial by Yi et al. in Science demonstrated that NMN supplementation improved muscle insulin sensitivity in older prediabetic women, raising NAD+ in skeletal muscle specifically — not just blood — which is a meaningful mechanistic advance.

Nicotinic Acid (Niacin)

Niacin was the first B3 vitamin identified and the first compound shown to raise NAD+ therapeutically — used for decades to lower triglycerides and raise HDL. It enters the Preiss-Handler pathway and is highly efficient at raising NAD+ in liver and adipose tissue. The clinical limitation is flushing — a prostaglandin D2-mediated skin vasodilation that occurs at doses needed for significant NAD+ elevation (≥100mg).

Extended-release niacin formulations reduce flush severity but introduced concerns about hepatotoxicity with long-term use. The cardiovascular benefits of niacin (independent of NAD+ considerations) became controversial after large randomized trials like AIM-HIGH and HPS2-THRIVE failed to show cardiovascular event reduction when added to statin therapy.

For pure NAD+ repletion purposes, niacin is the cheapest option and works, but flushing limits practical doses and the hepatotoxicity concern with extended-release formulations warrants caution. For individuals comfortable with acute flushing, immediate-release niacin at 100-500mg remains a cost-effective strategy.

Nicotinamide (NAM)

Nicotinamide — also called niacinamide — is the amide form of niacin, does not cause flushing, and enters the salvage pathway directly. It is cheap, widely available, and raises NAD+ in a dose-dependent fashion. The major caveat: at high doses (≥500mg), nicotinamide inhibits sirtuins and PARP in a feedback mechanism and inhibits NAMPT, the rate-limiting enzyme of the salvage pathway. This theoretical sirtuin inhibition would negate the primary benefit of raising NAD+.

Some longevity researchers use nicotinamide at lower doses (50-150mg) to provide NAD+ precursor without the inhibitory effects. Others avoid it entirely in favor of NR or NMN. The practical reality is that most commercial multivitamins contain 15-30mg of niacinamide — doses unlikely to have significant effects in either direction.

Sinclair's Protocol and the Resveratrol Question

David Sinclair, whose lab at Harvard Medical School has produced much of the foundational sirtuin research, has publicly disclosed taking 1g/day NMN with resveratrol and pterostilbene. Resveratrol was initially identified as an SIRT1 activator in the famous 2003 Nature paper by Howitz and Sinclair, though subsequent work showed resveratrol acts on SIRT1 primarily via a conformational mechanism that requires a fluorescent substrate in the original assay — sparking substantial controversy about whether resveratrol is a true SIRT1 activator in vivo.

Sinclair's position is that resveratrol and pterostilbene act as "SIRT1 co-activators" in combination with NMN, even if the original mechanism was more complicated than first reported. The evidence for resveratrol in humans is mixed; pterostilbene — a methylated analog with better bioavailability — has shown improvements in blood pressure and cognitive markers in some trials. Both are relatively safe at supplement doses.

Evidence Review: NAD+ Interventions at a Glance

NAD+ and the Hallmarks of Aging

The 2013 Cell paper by Lopez-Otin et al. defined nine hallmarks of aging that have since expanded to thirteen in the 2023 update. NAD+ decline intersects meaningfully with at least six of them, which is why restoring NAD+ is considered one of the broadest-acting interventions in the longevity toolkit.

Genomic Instability

DNA strand breaks accumulate with age and require PARP1 and PARP2 for efficient repair — both of which require NAD+. SIRT6 maintains telomere integrity and promotes DNA double-strand break repair in a NAD+-dependent manner. Insufficient NAD+ compromises both systems, allowing genomic damage to accumulate faster.

Epigenetic Alterations

SIRT1, SIRT2, SIRT3, and SIRT6 all regulate histone acetylation patterns. SIRT1 deacetylates H3K9ac and H4K16ac, maintaining heterochromatin and silencing repetitive elements. Loss of SIRT1 activity from NAD+ decline leads to global histone hyperacetylation, derepression of transposable elements, and epigenetic drift — a central mechanism in Sinclair's information theory of aging.

Mitochondrial Dysfunction

SIRT1 activates PGC-1α to drive mitochondrial biogenesis; SIRT3 maintains mitochondrial metabolic enzyme activity and antioxidant defense. NAD+ itself is required for the TCA cycle and electron transport chain. A triple insult: less NAD+ for bioenergetics, less SIRT1/SIRT3 for mitochondrial quality control, and less PGC-1α for generating new mitochondria.

Cellular Senescence

Senescent cells express high CD38 and low SIRT1. The SASP they secrete promotes CD38 upregulation in neighboring cells, spreading NAD+ depletion. Restoring NAD+ in senescent cells or adjacent cells may reduce SASP expression and improve the local tissue microenvironment — though it does not clear senescent cells the way senolytics do.

Deregulated Nutrient Sensing

SIRT1 deacetylates and modulates the activity of FOXO transcription factors, which regulate autophagy, stress resistance, and longevity across species. SIRT3 activates AMPK signaling indirectly. NAD+ decline thus impairs two of the major longevity-associated nutrient sensing pathways alongside mTOR signaling.

Inflammation (Inflammaging)

SIRT1 deacetylates and inhibits NF-κB p65, suppressing inflammatory gene transcription. SIRT2 regulates NLRP3 inflammasome activity. NAD+ decline permits unchecked NF-κB activation and contributes to the chronic low-grade inflammation characteristic of aging — which in turn further upregulates CD38, deepening the NAD+ deficit. Breaking this cycle is one of the most compelling theoretical justifications for NAD+ repletion in aged individuals.